Dec. 19, 2019
Intra-Cellular Therapies (ITCI) Inc. is a bio-pharmaceutical company founded by Paul Greenard, a Nobel-Prize winner who uncovered how therapies affect the inner-working of various cells in the body. They are headquartered in New York City, New York. The 30 Day Implied Volatility (IV) is currently at 354%, seeing a 250% rise from 104% over a 30 day period. The 30 Day ATM Straddle Premium is at 76.18%, having risen from 23.82%, with a growth of 52.36%.
A key factor driving the IV growth is that the FDA is expected to announce a pending decision on 27th December, regarding a new drug lumateperone, Intra-Cellular’s leading candidate for treating Schizophrenia. Schizophrenia could be the first indication where an approval could be received for Lumateperone, with the company most likely submitting a new application to endorse its use on patients with bipolar disorder.
Both these conditions are uncommon, which could lead to physicians leaning towards the drug for patients as a new treatment option. Analysts expect a peak value sales of $1BN for Lumateperone.
Raltin has no position in ITCI